Sarpogrelate controlled release - Yuyu PharmaAlternative Names: YY-984
Latest Information Update: 02 Dec 2015
At a glance
- Originator Yuyu
- Class Antiplatelets; Succinates; Vascular disorder therapies
- Mechanism of Action Serotonin 2A receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Peripheral arterial occlusive disorders